Novavax Inc
Research Novavax Inc (NVAX) on Bullrun: market cap USD 1.56B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVAX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.56B
- Financial periodQ2 2026
- RevenueUSD 56.70M
- Net income-USD 53.39M
- Free cash flow-USD 73.40M
- Gross margin74.9%
Valuation Snapshot
latest market cap is USD 1.56B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.12B | USD 440.30M | -USD 251.02M | 93.5% | 2.58 | USD 240.63M | USD 244.21M | -USD 127.75M |
| FY2024 | USD 682.16M | -USD 187.50M | -USD 101.90M | 70.3% | -1.23 | USD 530.23M | USD 230.42M | -USD 623.84M |
| FY2023 | USD 983.71M | -USD 545.06M | n/a | 65.1% | -5.41 | USD 568.51M | USD 229.08M | -USD 716.93M |
| FY2022 | USD 1.98B | -USD 657.94M | n/a | 54.5% | -8.42 | USD 1.34B | USD 448.43M | -USD 634.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.56B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.09B | 2.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.29B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 570.19M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 883.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 10.85B | n/a | n/a | n/a |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Novavax Inc's market cap?
Novavax Inc's market capitalization is USD 1.56B.
What does Novavax Inc do?
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.